Summary of Human Nuclear Sequence Variation Studies
| Authors | Year | Region | L | n | S | k | π |
| Hey | 1997 | PDHA1, X chr | 1.8 | 8 | 4 | 4 | 0.0015 |
| Zietkiewicz et al. | 1998 | Dystrophin, X chr | 7.6 | 250 | 35 | 36 | 0.0013 |
| Nachman et al. | 1998 | Introns from 7 loci, X chr | 11.4 | 10 | 20 | — | 0.0008 |
| Harris and Hey | 1999 | PDHA1, X chr | 4.2 | 35 | 25 | 11 | 0.0022 |
| Kaessman et al. | 1999 | Non coding region, X chr | 10.2 | 69 | 33 | 20 | 0.0005 |
| Jaruzelska et al. | 1999a | ZFX, X chr | 1.1 | 336 | 10 | 11 | 0.0011 |
| Dorit et al. | 1995 | ZFY, Y chr | 0.7 | 38 | 0 | 1 | 0 |
| Hammer | 1995 | YAP region, Y chr | 2.6 | 16 | 5 | 5 | 0.0004 |
| Whitfield et al. | 1995 | SRY, Y chr | 18.3 | 5 | 3 | 4 | 0.0003 |
| Jaruzelska et al. | 1999b | ZFY, Y chr | 0.7 | 205 | 1 | 2 | 0.00006 |
| Shen et al. | 2000 | SMCY, UTY1, DBY, DFFY, Y chr | 81 | 53 | 98 | — | 0.000052 |
| Li and Sadler | 1991 | 49 autosomal loci | 75 | 2 | — | — | 0.0011† |
| Fullerton et al. | 1994 | β-globin, chr 11 | 3.1 | 36 | 17 | 17 | 0.0014 |
| Harding et al. | 1997 | β-globin, chr 11 | 2.7 | 349 | 35 | 30 | 0.0018 |
| Clark et al. | 1998 | LPL, chr 8 | 9.7 | 142 | 88 | 88 | 0.0020 |
| Grimsley et al. | 1998 | HLA-H pseudogene, chr 6 | 0.3 | 34 | 15 | 11 | 0.0196 |
| Rieder et al. | 1999 | ACE, chr 17 | 24 | 22 | 78 | 13 | 0.0009 |
| Halushka et al. | 1999 | 75 genes | 190 | 149 | — | — | 0.0008 |
| Rana et al. | 1999 | MC1R, chr 16 | 0.95 | 242 | 6 | 6 | 0.0020 |
| Fullerton et al. | 2000 | ApoE, chr 19 | 5.5 | 192 | 22 | 31 | 0.0005 |
| This study | 2001 | psGBA, chr 1 | 5.4 | 100 | 18 | 25 | 0.0004 |
-
In the cases in which the X or the Y chromosomes were studied, the standardized π (nucleotide diversity) is shown (π values were multiplied by 4/3 or by 4, respectively, to make them comparable to autosomes).
-
↵L, length per locus is indicated as number of kilobases sequenced.
-
↵n, number of chromosomes.
-
↵S, number of segregating sites.
-
↵k, number of haplotypes observed.
-
↵chr, chromosome.
-
Nucleotide diversity for fourfold degenerate sites.











